Clinical trial · Observational
Omics Signature in the Diagnosis of Hypertension
Performance of an Omics-signature in the Diagnosis and Prognosis of Endocrine and Primary Hypertension
NCT02772315CI-TRIAL-00025638ENSAT-HTunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the validity and usefulness of omics signatures for improved identification and risk stratification of patients with endocrine hypertension and stratification of patients with primary hypertension.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hypertension | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| omics | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Hypertensive patients
- description
- Diagnostic procedures in patients with hypertension applying omics results
- interventionNames
- Other: omics
Primary outcomes (6)
- measure
- sensitivities of omics signatures for the diagnosis of subtypes of hypertension
- timeFrame
- 1 year
- description
- The proportion of patients with various subtypes of endocrine hypertension as identified by omics signature in patients in which subtypes have been identified by usual diagnostic algorithms
- measure
- specificities of omics signatures for the diagnosis of subtypes of hypertension
- timeFrame
- 1 year
- description
- The proportion of patients with non-endocrine hypertension as identified by omics signature in patients identified as having non-endocrine hypertension by usual diagnostic algorithms.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Aged from 18 to 75 years old * A signed and dated informed consent form * A diagnosis of hypertension defined either as: * Use of antihypertensive drug (s) * Arterial hypertension: in untreated patients this must be confirmed by daytime ambulatory blood pressure monitoring (ABPM), or home blood pressure monitoring, with blood pressure higher or equal to 135 mmHg for systolic blood pressure and/or higher or equal to 85 mmHg for diastolic blood pressure. In order to be eligible to participate in the nested case control study, a subject must also meet the following criteria: \- A conformed diagnosis of PA, PPGL or CS for case patients and PHT (exclusion of secondary forms) for their matched counterparts Exclusion Criteria: * Any severe comorbid conditions that, according to the attending physician, could decrease the life expectancy to less than 3 years * Any active malignancy unrelated to adrenal disease or PPGL * Guardianship for incapacity A potential control subject who meets any of the following criteria will be excluded from participation in the nested case controlled study in case of: * Existence of any other forms of secondary hypertension such as renal artery stenosis, renal disease, Munchausen's syndrome in which the patient induces hypertension regardless of method. * Drug-induced (included factitious use of illicit substances) hypertension
References
Publications (0)
Data not yet available
No reference posted for this study.